Skip to main content

Table 3 Day 1 and day 29 pharmacokinetic parameters (letrozole and nintedanib)

From: Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

LET

Mean Cmax (ng/ml)

Mean Tmax (h)

Mean AUC0-last (ng-h/ml)

NINT

Mean Cmax (ng/ml)

Mean Tmax (h)

Mean AUC0-last (ng-h/ml)

Level 1 day 1

100.2

0

2204

BS level 1 day 1

51

1.9

339

Level 1 day 29

89.4

4

2059

BS level 1 Day 29

50

1.1

519

Level 2 day 1

124.5

4

2782

BS level 2 day 1

65

2.0

599

Level 2 day 29

148.0

2

3170

BS level 2 day 29

92

2.0

941

 

ZW level 1 day 1

24

1.9

200

ZW level 1 day 29

28

1.1

367

ZW level 2 day 1

41

3.3

413

ZW level 2 day 29

67

3.0

824

  1. LET letrozole, NINT nintedanib, BS BIBF1120-BS, ZW BIBF1202-ZW